Stocktoria
Organogenesis Holdings Inc. ORGO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2016-12-02
Organogenesis Holdings Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | — | 76.0% | 75.4% | 76.7% | 75.6% |
| Operating margin | 7.9% | -0.3% | 2.9% | 4.9% | 15.5% |
| Net margin | 6.6% | 0.2% | 1.1% | 3.4% | 20.2% |
| FCF margin | -4.3% | 0.9% | 1.5% | -2.0% | 6.6% |
| Return on assets | 6.2% | 0.2% | 1.1% | 3.5% | 21.3% |
| Return on equity | 12.3% | 0.3% | 1.8% | 5.8% | 39.0% |
| Debt / equity | — | — | 0.24× | 0.27× | 0.31× |
| Current ratio | 3.62 | 3.69 | 2.80 | 2.97 | 2.74 |
| Revenue growth | 17.0% | 11.3% | -3.9% | -3.5% | 38.2% |
Source: SEC EDGAR filings · CIK 0001661181 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.